A loss of both cIAP1 and cIAP2 was described for cell lines highly responsive to IAP antagonists22,23, but in many cases, including glioma, changes in IAP amounts and treatment responsiveness can be highly heterogeneous24. Here, BIRC2 is linked to central nervous system cancer.